2023
DOI: 10.1186/s12865-023-00582-z
|View full text |Cite
|
Sign up to set email alerts
|

Tacrolimus reverses pemphigus vulgaris serum-induced depletion of desmoglein in HaCaT cells via inhibition of heat shock protein 27 phosphorylation

Zhimin Xie,
Xiangnong Dai,
Qingqing Li
et al.

Abstract: Background Glucocorticoids are the first-line treatment for Pemphigus vulgaris (PV), but its serious side effects can be life-threatening for PV patients. Tacrolimus (FK506) has been reported to have an adjuvant treatment effect against PV. However, the mechanism underlying the inhibitory effect of FK506 on PV-IgG-induced acantholysis is unclear. Objective The objective of this study was to explore the effect of FK506 on desmoglein (Dsg) expression… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

1
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 41 publications
1
0
0
Order By: Relevance
“…Moreover, results from cell dissociation assays suggest that administering tacrolimus, either alone or in combination with other medications, substantially increases cell adhesion in a human keratinocyte cell line (HaCaT cells) and mitigates the loss of cell adhesion induced by human induction. This corresponds to the function of TBX3 in metastatic OS samples, indicating the potential clinical application value of our study 61 . Thus, combining the aforementioned medications with existing mainstream clinical chemotherapeutic approaches (MAP) may provide a fresh perspective for enhancing OS treatment.…”
Section: Discussionsupporting
confidence: 64%
“…Moreover, results from cell dissociation assays suggest that administering tacrolimus, either alone or in combination with other medications, substantially increases cell adhesion in a human keratinocyte cell line (HaCaT cells) and mitigates the loss of cell adhesion induced by human induction. This corresponds to the function of TBX3 in metastatic OS samples, indicating the potential clinical application value of our study 61 . Thus, combining the aforementioned medications with existing mainstream clinical chemotherapeutic approaches (MAP) may provide a fresh perspective for enhancing OS treatment.…”
Section: Discussionsupporting
confidence: 64%